-+ 0.00%
-+ 0.00%
-+ 0.00%
Voronoi Wins Australian Approval to Amend VRN110755 Phase 1/2 Trial
Share
Listen to the news
Voronoi Wins Australian Approval to Amend VRN110755 Phase 1/2 Trial
  • Voronoi secured Australian HREC approval on Nov. 18, 2026, for protocol changes to its Phase 1/2 VRN110755 trial.
  • The trial targets approximately 355 patients with EGFR-mutated advanced non-small cell lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voronoi Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261119900540), on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending